Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Melanocortin 4 Receptor (MC4R) Agonists -Pipeline Insights, 2016

(, August 12, 2017 ) Publisher's, "Melanocortin 4 Receptor (MC4R) Agonists-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Melanocortin 4 Receptor (MC4R) Agonists. The Publisher's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Melanocortin 4 Receptor (MC4R) Agonists. Publisher's Report also assesses the Melanocortin 4 Receptor (MC4R) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

For more information about this report:

Report Scope

- The report provides competitive pipeline landscape of Melanocortin 4 Receptor (MC4R) Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Melanocortin 4 Receptor (MC4R) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Melanocortin 4 Receptor (MC4R) Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reason to Buy

- Complete MOA intelligence and complete understanding over therapeutics development for Melanocortin 4 Receptor (MC4R) Agonists
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Melanocortin 4 Receptor (MC4R) Agonists pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

Request Sample Copy at

- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Table of Contents
- Melanocortin 4 Receptor (MC4R) Agonists Overview
- Melanocortin 4 Receptor (MC4R) Agonists Disease Associated
- Melanocortin 4 Receptor (MC4R) Agonists Pipeline Therapeutics
- Melanocortin 4 Receptor (MC4R) Agonists Therapeutics under Development by Companies
- Melanocortin 4 Receptor (MC4R) Agonists Filed and Phase III Products
- Comparative Analysis
- Melanocortin 4 Receptor (MC4R) Agonists Phase II Products
- Comparative Analysis
- Melanocortin 4 Receptor (MC4R) Agonists Phase I and IND Filed Products
- Comparative Analysis
- Melanocortin 4 Receptor (MC4R) Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Melanocortin 4 Receptor (MC4R) Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Melanocortin 4 Receptor (MC4R) Agonists - Discontinued Products
- Melanocortin 4 Receptor (MC4R) Agonists - Dormant Products
- Companies Involved in Therapeutics Development for Melanocortin 4 Receptor (MC4R) Agonists

Inquire before Buying at

Rajat Sahni


Source: EmailWire.Com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News

[CaRP] XML error: EntityRef: expecting ';' at line 51 - This appears to be an HTML webpage, not a feed. is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.

GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | | i-Canada-News.Com | | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | | | | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | - Medicl Newswire and Press Release service of GroupWeb Media LLC